Online citations, reference lists, and bibliographies.
← Back to Search

18F-fluoro-2-deoxy-d-glucose Positron Emission Tomography/computed Tomography Fused Imaging In Malignant Mesothelioma Patients: Looking From Outside Is Not Enough.

E. Roca, S. Laroumagne, T. Vandemoortele, S. Berdah, H. Dutau, F. Maldonado, P. Astoul
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Malignant mesothelioma (MM) is an uncommon neoplasm with a poor prognosis usually associated with asbestos exposure. 18F-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) has become an invaluable tool for the diagnosis, staging, and prognosis of this severe disease as it combines both anatomic and functional information in a single imaging procedure, allowing for improved management of this disease. For many authors, 18F-FDG-PET/CT is the cornerstone of the pre-therapeutic evaluation of mesothelioma patients, particularly when multimodal therapy (including extra-pleural pneumonectomy or omentectomy) is considered. However, while characteristic patterns have been reported as predictive of macroscopic pleural or peritoneal involvement, false negative findings are possible, both for pleural and peritoneal mesothelioma, during the initial diagnosis or during the patient's surveillance as illustrated by this report of three cases of suspected MM with negative PET/CT. This report highlights the limitations of PET/CT in the diagnostic evaluation of MM and the importance of histopathological confirmation by thoracoscopy and/or laparoscopy, which remain the most important diagnostic procedures in MM.
This paper references
Prognostic Factors According to the Treatment Schedule in Malignant Pleural Mesothelioma
Guntulu Ak (2009)
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
Prognostic Value of 18F-FDG Standard Uptake Value by Integrated PET/CT in the Staging of Malignant Pleural Mesothelioma
G. Genestreti (2012)
18F-FDG-PET/CT to Select Patients with Peritoneal Carcinomatosis for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
C. Pfannenberg (2009)
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
Case 2.3
C. Lee (2014)
The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases.
A. Orki (2009)
Case 1-2
R. Spetzler (2013)
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
PET for the evaluation of pleural thickening observed on CT.
H. Kramer (2004)
18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma.
Q. Cao (2012)
The Role of 18F-FDG PET/CT in the Evaluation of Ascites of Undetermined Origin
M. Zhang (2009)
Case 3.2
C. Lee (2014)
Relevance of FDG-PET-CT scan for the evaluation of local pleural invasion assessed by thoracoscopy in malignant pleural mesothelioma
V. Pinelli (2012)
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
A. Carretta (2000)
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid Histology
Kyuichi Kadota (2012)

This paper is referenced by
Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
Sabrina Di Bartolomeo (2016)
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma
K. Kitajima (2016)
Occupational Lung Diseases
J. Chung (2019)
Value of FDG PET/CT in the Management of Mesothelioma
Mohamad Faizul Abu Hanifa (2016)
ACR Appropriateness Criteria® Occupational Lung Diseases.
C. Cox (2020)
Scrotal peritoneal mesothelioma on PET/CT.
S. Ozguven (2014)
18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
F. Lococo (2020)
Positron Emission Tomography/Computed Tomography for the Pleural Staging of Malignant Pleural Mesothelioma: How Accurate Is It?
V. Pinelli (2015)
Prognostic factors in malignant pleural mesothelioma: a retrospective study of 60 Turkish patients.
A. Koyuncu (2015)
Abord de l’épanchement pleural métastatique symptomatique cas clinique interactif
Philippe Astoul (2014)
The potential value of volume-based quantitative PET parameters and increased bone marrow uptake for the prediction of survival in patients with malignant pleural mesothelioma
O. Ozmen (2016)
Treating Malignant Pleural Mesothelioma : an update on the situation at the dawn of 2014
Value of contrast CT in combination with PET/CT in mesothelioma staging: Optimal protocol for initial assessment
M. Houseni (2017)
ACR Appropriateness Criteria®
Jamie Marko (2015)
Diagnostic Value of Computed Tomography Imaging Features in Malignant Pleural Mesothelioma
M. Fortin (2019)
La thoracoscopie médicale en pratique pneumologique : expérience du CHU de Liège
B. Duysinx (2019)
Semantic Scholar Logo Some data provided by SemanticScholar